RAPTOR ANNOUNCES POSITIVE RESULTS FOR CONVIVIA(TM) PROGRAM -
Raptor reports promising results from Phase IIa ALDH2 deficiency study -
RPTP: To Present At Rodman & Renshaw Investment Conference @ 09:30 ET [delayed] -
Raptor partners with CHU d'Angers for Phase II Huntington's disease trial -
RPTP: Agreement Centre Hospitalier Universitaire d'Angers in France -
Raptor Pharmaceuticals Provides Update on Targeting Platforms -
RPTP: To Present At BIO Investor Conference @ 16:45 ET [delayed] -
Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences -
Raptor initiates dosing in Phase IIa non-alcoholic steatohepatitis trial -
RPTP: Begins Phase 2a Trial of Cysteamine for Non-Alcoholic Steatohepatitis -
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) -
Raptor signs collaboration agreement with University of California -
RAPTOR PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT -
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease -
Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board -
Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board -
Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board -